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Quantitative electroencephalography EEG slowing was evident in dementia with Lewy bodies (DLB) and Parkinson’s disease dementia
(PDD) and less in Alzheimer’s disease (AD) patients compared to controls.
 Dominant rhythm variability was larger in AD but only correlated with cognitive fluctuations in DLB.
 QEEG variables classified DLB and AD patients with high sensitivity and specificity.
a b s t r a c t
Objective: We investigated for quantitative EEG (QEEG) differences between Alzheimer’s disease (AD),
dementia with Lewy bodies (DLB) and Parkinson’s disease dementia (PDD) patients and healthy controls,
and for QEEG signatures of cognitive fluctuations (CFs) in DLB.
Methods: We analysed eyes-closed, resting state EEGs from 18 AD, 17 DLB and 17 PDD patients with mild
dementia, and 21 age-matched controls. Measures included spectral power, dominant frequency (DF),
frequency prevalence (FP), and temporal DF variability (DFV), within defined EEG frequency bands and
cortical regions.
Results: DLB and PDD patients showed a leftward shift in the power spectrum and DF. AD patients
showed greater DFV compared to the other groups. In DLB patients only, greater DFV and EEG slowing
were correlated with CFs, measured by the clinician assessment of fluctuations (CAF) scale. The diagnos-
tic accuracy of the QEEG measures was 94% (90.4–97.9%), with 92.26% (80.4–100%) sensitivity and 83.3%
(73.6–93%) specificity.
Conclusion: Although greater DFV was only shown in the AD group, within the DLB group a positive DFV –
CF correlation was found. QEEG measures could classify DLB and AD patients with high sensitivity and
specificity.
Significance: The findings add to an expanding literature suggesting that EEG is a viable diagnostic and
symptom biomarker in dementia, particularly DLB.
 2018 International Federation of Clinical Neurophysiology. Published by Elsevier B.V. This is an open
access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).1. Introduction
Dementia with Lewy bodies (DLB) is a common type of demen-
tia after Alzheimer’s disease, accounting for approximately 10–15%
of cases at autopsy (McKeith et al., 2004). DLB is associated with
quality of life and significant carer burden. It is frequently under-
diagnosed and often misdiagnosed as AD, especially at early stages
where both diseases manifest with similar cognitive deficits
(Metzler-Baddeley, 2007). Estimates of sensitivity and specificity
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2017) have been quite variable but have a common tendency for
relatively high specificity but lower sensitivity (Huang et al.,
2013). The fact that DLB patients are sensitive to neuroleptics
(McKeith et al., 1992), and demonstrate a faster disease progres-
sion compared to other dementias (Ballard et al., 2001), underpin
the necessity to improve diagnostic accuracy for this group of
patients.
Cognitive fluctuations (CFs) are one of the core symptoms of
DLB and refer to spontaneous alterations in cognition, attention
and arousal (McKeith et al., 2017). CFs are of clinical importance
as they have been correlated with visual hallucinations (Varanese
et al., 2010), impairment in daily activities and care burden. More-
over, CFs are an important diagnostic feature for DLB as their
prevalence reaches 90% of cases, compared to just 20% of AD and
29% of Parkinson’s disease dementia (PDD; Ballard et al., 2002).
CFs are also qualitatively different between DLB and AD as in the
former case they relate more to executive and perceptual perfor-
mance, while in the later they are primarily linked to memory
impairment (Zupancic et al., 2011). The Clinician Assessment of
Fluctuation (CAF) is a clinical scale devised for the psychometric
assessment of CFs (Walker et al., 2000). Although CAF is regarded
as a fairly reliable measure of CFs if used by an experienced clini-
cian (Van Dyk et al., 2016), the high variability in fluctuation sever-
ity and duration of confusional episodes, along with difficulties for
informants in separating out what are true intrinsic fluctuations
from what are simply responses to external stressors, impose a
considerable limitation in CF identification (Bradshaw et al., 2004).
Electroencephalography is an emerging modality for differential
diagnosis between dementia subtypes as it is simple, cost-
effective, easily accessible and non-invasive compared to imaging
approaches. The most prominent QEEG finding in DLB and PDD is
a shift of power and dominant frequency (DF) from the alpha fre-
quency range towards high-theta, described as ‘‘EEG slowing”. This
EEG slowing is most prevalent posteriorly (Briel et al., 1999) and
although it is also observed in AD patients (Jackson et al., 2008),
it is not as prominent as in the Lewy body diseases – DLB and
PDD. In studies quantifying differences between DLB or DLB/PDD,
or AD and controls, QEEG variables such as coherence (Snaedal
et al., 2012), temporal dominant frequency variability (DFV)
(Andersson et al., 2008), power ratio between bands and statistical
measures such as Granger causality (Garn et al., 2017), have all
achieved high diagnostic sensitivity and specificity, reaching
100% in the latter study.
Previous investigations have found electrophysiological correla-
tions of CFs in DLB patients. Early work using quantitative elec-
troencephalography (QEEG) has shown a correlation between
epoch-by-epoch DFV and CFs in DLB patients compared with
healthy controls (Walker et al., 2000). Later work also showed that
DLB patients with CFs had greater DFV compared to AD patients in
posterior brain regions, and used the DFV together with other
QEEG measures to classify AD, PDD-CFs, PDD-without CFs and
DLB patients and controls (Bonanni et al., 2008). More recently, a
multi-centre cohort analysis has verified these results (Bonanni
et al., 2016).
The aforementioned findings of QEEG signatures in DLB in addi-
tion to the fact that the QEEG measures were shown to be corre-
lated with the clinical phenotype of DLB and specifically with
CFs, suggest that the QEEG could be utilised to investigate for a
neurophysiological divergence between DLB and other dementias.
The QEEG investigations performed so far have not yet managed to
identify differences (Engedal et al., 2015; Garn et al., 2017)
between DLB and PDD. Generally, these Lewy body dementia
(LBD) subtypes demonstrate great similarities in neuropathological
processes, symptommanifestation and treatment. However, DLB istypically characterised by greater executive dysfunction, more psy-
chiatric symptoms, poorer response to levodopa (L-DOPA) and
greater amyloid burden compared to PDD (Edison et al., 2008).
Moreover, the onset of motor symptoms precedes that of dementia
in PDD while in DLB, dementia appears concurrently or before
motor symptoms (McKeith et al., 1992). These discrepancies may
indicate differences in the spatio-temporal sequence of pathology,
with a predominant brain-stem start and rostral progression in
PDD and a cortical inception in DLB (Beyer et al., 2007). Potential
QEEG differences between PDD and DLB are of research interest,
as they could provide insight for better understanding these LBD
subtypes.
Earlier QEEG studies focused on investigating the capacity of
such measures in aiding DLB differential diagnosis in clinical set-
tings. Hence, they utilized methods such as assessment by visual
observation (Bonanni et al., 2008), or attempted to develop an
online method that performs analysis during and right-after EEG
acquisition (Garn et al., 2017). Here we took a less clinically-
orientated approach, as our primary goal was to characterise and
compare the resting EEG rhythm in AD, DLB and PDD patients
and in relation to healthy controls, and to investigate for DLB speci-
fic signatures of CFs. Thus, we performed extensive pre-processing
analysis of the EEG signal and a thorough analysis for differences in
QEEG measures within different frequency ranges and brain
regions, between diagnostic groups. Based on the literature, we
hypothesized that dementia patients will exhibit a differential pat-
tern in the distribution of QEEG measures of power and DF within
different frequency ranges compared to healthy controls, and that
these QEEG measures in addition to DF variability in time (DFV)
will also differ between the dementia groups. We also hypothe-
sized that greater DFV will only characterise LBDs and possibly
only DLB, and that greater DFV will correlate with more CFs within
these groups. Finally, to assess the possible utility of these mea-
sures in the development of biomarkers, the QEEG measures that
were found to be significantly different between groups were used
to predict dementia diagnosis.
2. Material and methods
2.1. Diagnostic groups
Initially we pre-processed EEG data from 21 healthy controls,
19 AD, 20 DLB and 20 PDD participants (Table 1 for the demo-
graphic data of the final groups). Patients were individuals who
were referred to local old age psychiatry and neurology services
and diagnosis was determined by two independent experienced
clinicians (Alan J. Thomas and John-Paul Taylor). Controls were
age-matched volunteers. Patients with DLB fulfilled the 2005 and
2017 revised criteria for probable DLB (McKeith et al., 2005,
2017) and patients with PDD fulfilled the criteria for probable
PDD (Emre et al., 2007). Individuals with AD met the revised crite-
ria of the National Institute of Neurological and Communicative
Diseases and Stroke/AD and Related Disorders Association for
probable AD (McKhann et al., 2011). The CAF score was assessed
by the clinicians and CFs were defined on the basis that they were
typical of those seen in DLB and internally driven rather than a
response to external environmental factors. Healthy participants
demonstrated no evidence of dementia as determined by the Cam-
bridge Cognitive Examination (CAMCOG) score (>80) and from
clinical history. Exclusion criteria for all participants included sig-
nificant history of neurological or psychiatric conditions. Prescrip-
tions of acetylcholinesterase inhibitors (AChEIs), memantine and
dopaminergic medications were allowed. Ethical approval was
provided by the Northumberland Tyne and Wear NHS Trust and
Newcastle University ethics committee.
Table 1
Demographics table for the healthy control (N = 21), Alzheimer’s disease (AD; N = 18), dementia with Lewy bodies (DLB; N = 17) and Parkinson’s disease dementia (PDD; N = 17)
groups that were used for our analysis. L-DOPA = levo-dopa, LED = L-DOPA equivalent dose, AChEIs = acetylcholinesterase inhibitors, MMSE = Mini mental state examination, CAF
= Clinician’s assessment of fluctuations scale, UPDRS = Unified Parkinson’s disease rating scale, NPI = Neuropsychiatric inventory total score. Although it is not shown in the table,
1 PDD patient (5.9%) was on memantine.
Controls (N = 21) AD (N = 18) DLB (N = 17) PDD (N = 17)
Age in yrs ± SD 76.19 ± 5.32 76.06 ± 7.81 75.71 ± 5.34 75.44 ± 4.66
Males (%) 66.7% 88.9% 88.2% 100%
L-DOPA – 0% 52.9% 100%
LED – 0% 348.94 423.42
AChEIs – 94.4% 88.2% 76.5%
Age at diagnosis (yrs ± SD) – 74.64 ± 7.63 73 ± 5.11 74.07 ± 6.29
Diagnosis duration (yrs ± SD) – 1.5 ± 0.9 1.08 ± 0.70 0.94 ± 0.73
MMSE 29.19 ± 0.87 23.67 ± 1.68 25 ± 2.89 23.94 ± 2.59
CAF – 0.47 ± 0.87 2.76 ± 3.78 6.59 ± 4.29
NPI total – 7.29 ± 7.61 8 ± 5.27 20.35 ± 12.9
UPDRS 1.14 ± 1.42 1.67 ± 1.61 13.82 ± 5.32 27.06 ± 11.44
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High-density, eyes-closed resting-state EEG recordings were
obtained using 128 channel ANT Waveguard caps (ANT Neuro,
Netherlands) with an Ag/AgCl electrode montage set according to
the 10-5 placement system (Oostenveld and Praamstra, 2001).
Electrode impedance with kept below 5 kX. A reference electrode
(Fz) was used, no filters were applied during acquisition and the
sampling frequency was set at 1024 Hz. The patients that received
medication had normally taken AChEIs at least 4 h before while the
time of the last Levodopa dose was 1–3 h prior to the EEG session.2.3. Pre-processing
Pre-processing of the EEG recordings was performed off-line
after acquisition on the MATLAB environment (MATLAB 8.5, The
MathWorks Inc., Natick, MA, 2015), using the EEGLAB toolbox ver-
sion 13 (Delorme and Makeig, 2004). The EEG signal was filtered
with a 4 Hz high-pass and a 46 Hz low-pass filter. Lower frequen-
cies were filtered out as they imposed noise on the higher frequen-
cies that were of more interest, and because the EEG generally has
a limited accuracy in estimating very low and very high frequen-
cies (Niedermeyer and Lopes da Silva, 2004). A notch filter was
applied at 50 Hz. Recordings from all electrodes were visually
inspected in the power-time domain and rejected if they had a kur-
tosis value over 3, or if they contained clear and consistent artifacts
such as electrooculogram (EOG) and electromyogram (EMG) arti-
facts. The number of channels removed was kept to the minimum
possible (mean = 17.7 ± 6.7, min. = 0, max. = 33).
Independent component analysis (ICA) was used to accurately
estimate and remove the presence of additional ocular, muscular,
and other neuronal activity (Kropotov and Kropotov, 2009). Indi-
vidual recordings were reduced to 30 principal components and
then decomposed using the extended RUNICA algorithm (Bell
and Sejnowski, 1995; Delorme and Makeig, 2004). Components
representing existing templates for muscular, ocular, and electrical
(50 Hz line noise) artefacts (Jung et al., 2000) were rejected (mean
= 5.2 ± 1.6, min. = 0, max. = 9) and the remaining ICs remixed. The
recordings were then segmented into 2-s long epochs and were
inspected for any remaining artefacts. Epochs containing large arti-
facts were removed across channels, in a conservative manner.
Finally, the removed channels were replaced using spherical spline
interpolation (Ferree, 2006). As a final step, the EEG montage was
changed to average reference.2.4. Variable extraction
The power spectral density (PSD) for each 2-s epoch was
estimated using Bartlett’s method (Bartlett, 1950) with a 0.25 Hzfrequency resolution using a 4-s FFT (fast Fourier transform) size
and a Hamming window, for each electrode. To compensate for
the between subject variability in factors such as brain neurophys-
iology, anatomy and physical tissue properties, the data were
transformed to relative power spectral density (rPSD; Eq. (1);
Rodriguez et al., 1999). The rPSD was extracted for each time point
of each epoch (sampling frequency = 1024 Hz), and for each elec-
trode. Then, for each epoch of a recording, the power was averaged
across electrodes for each of four regions: frontal, central, posterior
and lateral (Fig. 1). Seven subjects were rejected from further anal-
ysis due to an insufficient number of clean data (<47 epochs). For
the remaining 73 subjects (21 healthy controls, 18 AD, 17 DLB
and 17 PDD; Table 1), only the first 47 epochs of extracted power
per region were utilised (total length of 94 s).
gðf Þ ¼ gðf ÞP
f gðf Þ
ð1Þ
Equation (1): Calculation of the relative PSD/power ðgÞ across the
power spectrum (4–46 Hz). At each point in the frequency spectrum
the amplitude (gðf Þ) is divided by the sum of all amplitudes across
the frequency spectrum (
P
f gðf Þ) (Kropotov and Kropotov, 2009).
The mean power distributed in each of three frequency bands:
theta (4–7.75 Hz), alpha (8–13.75 Hz), beta (14–20.75 Hz), was
extracted as a percentage of the total power in that range, across
epochs per region (Table 2; Fig. 2). Higher frequencies were
excluded as they are prone to contamination by electromyogram
rhythms (Whitham et al., 2007). The DF – the frequency with the
highest power between 4 Hz and 20.75 Hz – was extracted for each
epoch to calculate the mean DF and DF variability (DFV; SD from
the mean DF) across epochs, for the slow-theta (4–5.5 Hz), fast-
theta (5.5–7.75 Hz; defined by others as pre-alpha; Bonanni
et al., 2008), theta, alpha and theta/alpha (4–13.75 Hz) frequency
ranges (Table 3; Fig. 2). Since the DF was limited within the
theta-alpha range, beta band activity was excluded. The theta-
alpha DF was used to calculate the Frequency Prevalence (FP) dis-
tribution, which is the percentage of epochs having a DF falling
within the slow-theta, fast-theta and alpha frequency ranges
(Table 3; Fig. 2). These measures were calculated for each patient,
for each diagnostic group and for each band and region
combination.
2.5. Statistical analysis
The mean power, theta-alpha DF and theta, alpha and theta-
alpha DFV were statistically compared using repeated measures
ANOVA, for region as the within-subjects factor and diagnosis as
the between-subjects factor. When a significant interaction was
found we followed up by univariate ANOVA and post hoc analysis
with a Bonferonni correction. The DFV (for all frequency ranges)
Fig. 1. Placement of the 128 electrodes according to the 10-5 placement system.
The signal recorded from the electrodes indicated with black colour was selected
out as it was deemed too noisy. The colours indicate the grouping of the electrodes
into four regions: blue = frontal, green = central, purple = posterior, yellow = lateral.
(For interpretation of the references to colour in this figure legend, the reader is
referred to the web version of this article.)
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achieve homogeneity of variance/homoscedasticity. Heteroscedas-
ticity could not be solved for the theta and alpha DF and hence we
performed Welch’s ANOVA followed by the Games-Howell test. To
statistically compare the distribution of the FP in the slow-theta,
fast-theta and alpha frequency ranges we performed Kruskal-
Wallis H test followed by post hoc analysis. Pearson’s product-
moment correlation and Spearman’s rank correlation were used
to investigate for correlations between these variables and the
CAF score, the MMSE score and the levodopa equivalent dose
(LED), for each diagnostic group. Manual correction for multiple
comparisons by appropriating the level of a significance (a/N)
was performed for the non-parametric statistical analyses and for
the correlation analyses, where Bonferonni correction was not
available with the statistical software.
In order to assess the capacity of the QEEG variables that were
significantly different between the AD and DLB, and the DLB and
PDD groups to predict diagnosis, the generalised estimating equa-
tions (GEE) procedure were used. This method allows the analysisTable 2
The mean percentage of the total power distributed in each of three frequency bands: the
posterior, lateral, for each group: healthy controls (N = 21), Alzheimer’s disease (AD; N = 18
= 17) patients.
Regions Controls
Theta Frontal 20.19 ± 5.22
Central 19.18 ± 4.96
Posterior 19.79 ± 5.77
Lateral 19.32 ± 5.29
Alpha Frontal 35.12 ± 5.66
Central 34.74 ± 5.11
Posterior 38.91 ± 6.04
Lateral 35.41 ± 5.10
Beta Frontal 44.69 ± 7.09
Central 46.07 ± 6.75
Posterior 41.30 ± 7.09
Lateral 45.27 ± 7.71of repeated measurements without the assumption for normal dis-
tribution (Carr and Chi, 1992). The QEEG variables that introduce
multicollinearity to the model (variance inflation factor >5) were
excluded from this analysis. Region was defined as the within-
subjects variable, diagnosis as the between-subjects variable and
the QEEG variables and the CAF score as the co-factors. The vari-
ables that significantly predicted diagnosis were then used to cal-
culate the receiver operating characteristic (ROC) curve, and obtain
the area under the curve (AUC), sensitivity and specificity with
asymptotic confidence intervals. The sensitivity/specificity cut-off
was determined using Youden’s index.
3. Results
3.1. Data and demographics
Data from a total of 73 individuals (21 healthy controls, 18 AD,
17 DLB, 17 PDD; Table 1) were further analysed after data extrac-
tion. Participants were well matched for age at diagnosis and age at
the time of the recording (p > 0.05), as well as MMSE score (p >
0.05). The PDD and DLB groups had significantly higher CAF scores
than AD patients (p < 0.01; p < 0.05 respectively), with the PDD
group also having a higher CAF score than the DLB group (p <
0.01). Lastly, the neuropsychiatric inventory (NPI) total and Unified
Parkinson’s disease rating scale (UPDRS) scores were higher in the
DLB/PDD subjects compared to the other groups, and in the PDD
compared to the DLB group (p < 0.01).
3.2. EEG slowing
We found a significant effect of diagnosis on the mean power in
the theta: F (3, 69) = 39.48, p < 0.01, alpha: F (3, 69) = 14.49, p < 0.01
and beta: F (3, 69) = 12.825, p < 0.01 ranges (Table 2; Fig. 3). In all
regions, PDD and DLB groups had higher theta power than AD
patients and healthy controls (p < 0.01). In the alpha and beta
ranges the opposite pattern was observed. Specifically, in the alpha
band, controls had significantly higher power than PDD patients in
all regions (p < 0.01), and compared to DLB patients frontally, pos-
teriorly and laterally (p < 0.01). Moreover, AD patients had greater
alpha power than PDD patients posteriorly and laterally (p < 0.01),
and also to DLB patients frontally (p < 0.05), posteriorly and later-
ally (p < 0.01). In the beta range, DLB patients had lower power
than AD patients and controls in all regions (p < 0.01). PDD patients
had lower power than healthy controls frontally and centrally (p <
0.01) and posteriorly and laterally (p < 0.05), and from AD patients
frontally, posteriorly (p < 0.05) and centrally (p < 0.01).
We also found a significant effect of diagnosis in the second
measure of interest, the mean theta-alpha DF (F (3, 69) = 36.78,
p < 0.01), which was significantly higher in all cortical regions inta (4–7.75 Hz), alpha (8–13.5 Hz), beta (14–30.75 Hz), in each region: frontal, central,
), dementia with Lewy bodies (DLB; N = 17) and Parkinson’s disease dementia (PDD; N
AD DLB PDD
24.57 ± 6.26 37.63 ± 6.36 35.89 ± 7.46
23.02 ± 6.13 36.90 ± 7.05 35.33 ± 6.37
23.51 ± 6.63 39.62 ± 7.53 39.10 ± 7.63
24.39 ± 6.53 36.96 ± 6.07 35.35 ± 7.30
32.11 ± 4.31 28.96 ± 5.10 27.42 ± 2.57
32.61 ± 4.47 29.84 ± 4.91 29.04 ± 2.28
35.49 ± 5.81 29.26 ± 5.75 23.91 ± 2.50
33.43 ± 4.00 28.57 ± 4.98 26.75 ± 2.34
43.32 ± 7.03 33.40 ± 3.74 36.69 ± 7.52
44.37 ± 6.71 33.26 ± 3.85 35.65 ± 6.20
40.99 ± 8.38 31.11 ± 5.36 31.72 ± 7.67
42.17 ± 6.59 34.47 ± 5.52 37.90 ± 7.80
Fig. 2. Schematic diagram illustrating the process of extracting each of the four main quantitative EEG variables used in this study, for one participant in the posterior region.
The filtered, pre-processed EEG signal on each of the electrodes in posterior derivations (N = 35) is windowed in 2 s long epochs. The signal undergoes fast-Fourier transform
(FFT) and using Bartlett’s method the absolute power spectral density (PSD) is calculated for each epoch, for each electrode. The relative PSD (rPSD) is then calculated to
normalize the signal. The mean rPSD is obtained across posterior electrodes, for each epoch (up to 47 epochs) of the recording, and the percentage of the total power in the 3–
20.75 Hz range allocated to the theta (4–7.75 Hz), alpha (8–13.75 Hz) and beta (14–20.75 Hz) frequency ranges is calculated. The frequency with the highest power within the
slow-theta (4–5.5 Hz), fast-theta (5.5–7.75 Hz), alpha and theta-alpha (4–13.75 Hz) frequency ranges was identified within each epoch, and that value corresponded to the
dominant frequency (DF). The mean DF and the standard deviation of the mean DF (DF variability; DFV) across epochs were then calculated. Finally, the DF within each epoch
was assessed and was characterised to be in the slow-theta, fast-theta or alpha range. The epochs that were characterised by a DF within each of these ranges are shown as a
percentage of the total number of epochs. These percentages were the slow-theta, fast-theta and alpha frequency prevalence (FP). The same procedure was followed for the
other three cortical regions.
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(Table 3, Fig. 4). The mean theta DF was significantly higher in con-
trols compared to the PDD group frontally, to the AD, DLB and PDD
groups centrally and posteriorly, and to the DLB and PDD groups
laterally. Significant differences were also found between groups
in the alpha DF, in all regions. Specifically, the DLB group had sig-
nificantly lower alpha DF than the control and AD group in all
regions. The PPD group had higher alpha DF than the DLB group
frontally, the AD group centrally and posteriorly and the control
group laterally (Fig. 4). A trend for a greater alpha DF in the AD
compared to the control group was observed, but was not verified
by the statistical analysis.
Formeasures of frequency prevalence (FP; the percentage distri-
bution of the theta-alpha DF in time in the slow-theta, fast-theta
and alpha frequency ranges; Fig. 5, Table 3), the mean alpha FP
was significantly higher in controls compared to all disease groups
(p < 0.01), and in AD patients compared to DLB and PDD patients (p
< 0.01), in all regions. In the fast-theta range the opposite pattern
was observed, with controls exhibiting lower FP compared to AD
patients frontally (p < 0.01), and to DLB and PDD patients in all
regions (p < 0.01). Finally, in the slow-theta range controls had sig-
nificantly lower FP than AD patients frontally (p < 0.01), centrally
and posteriorly (p < 0.05), and to DLB and PDD patients in all regions
(p < 0.01). AD patients also have significantly lower slow-theta FP
than PDD patients frontally and centrally (p < 0.05).3.3. Dominant frequency variability
Comparisons of the DFV between groups for different frequency
band and region combinations revealed a significant effect of diag-
nosis in the theta/alpha (F (3, 69) = 2.77, p < 0.05 and alpha (F (3, 69)
= 6.29, p < 0.01) ranges (Fig. 6), but not in the theta range. In thetheta-alpha band, the AD group had a significantly higher DFV
compared to the control, DLB and PDD groups in the frontal, central
and posterior regions, and only to the DLB group laterally. In the
alpha band, AD patients had significantly higher DFV compared
to the DLB group centrally, and to DLB and controls posteriorly.
To further validate this finding we have included a short analysis
on the effect of each electrode on the DFV in AD and DLB patients
(Supplementary Material 1).3.4. Correlations
We assessed correlations between CFs as measured by CAF and
DFV measures similarly to previous studies (Walker et al., 2000),
and with QEEG measures of slowing for all the different diagnostic
groups and each band and region. This analysis revealed that
within the DLB group only, there was a strong correlation between
the CAF score and the theta DFV in the central (r = 0.789, p < 0.000),
posterior (r = 0.652, p < 0.005) and lateral regions (r = 0.805, p <
0.000). A positive, DLB specific correlation with CAF was also found
with slow-theta FP in the frontal (r = 0.679, p = 0.003), central (r =
0.747, p = 0.001), posterior (r = 0.792, p < 0.001) and lateral (r =
0.794, p = 0.001) regions. A correlation between the CAF and MMSE
score was only found in the PDD group (r = 0.671, p < 0.05), while
no significant correlation was found for any variable and the LED,
for any group and region.3.5. Exploratory GEE and ROC curve analysis
GEE analysis was performed for the variables that were signifi-
cantly different between the AD and DLB diagnostic groups (theta
power, alpha power, theta-alpha DFV, alpha DFV, alpha DF and
fast-theta FP). The alpha-theta DF and alpha FP were rejected from
Table 3
The mean dominant frequency (DF) ± DFV (mean SD of the DF), DFV ± SD and frequency prevalence (FP) ± SD for the theta (4–7.75 Hz), slow-theta (4–5.5 Hz), fast-theta (5.75–7
Hz), alpha (8–13.75 Hz) and theta-alpha (4–13.75 Hz) frequency ranges in each region: frontal, central, posterior, lateral, for each group: healthy controls (N = 21), Alzheimer’s
disease (AD; N = 18), dementia with Lewy bodies (DLB; N = 17) and Parkinson’s disease dementia (PDD; N = 17) patients.
Regions Variables Controls AD DLB PDD
Theta Frontal DF ± SD 6.93 ± 0.4 6.57 ± 0.54 6.49 ± 0.60 6.26 ± 0.31
DFV ± SD 0.93 ± 0.25 0.98 ± 0.24 0.73 ± 0.24 0.80 ± 0.19
FP ± SD 19.55 ± 22.14 44.92 ± 24.54 82.48 ± 21.00 91.36 ± 8.29
Central DF ± SD 7.11 ± 0.33 6.67 ± 0.59 6.65 ± 0.52 6.51 ± 0.35
DFV ± SD 0.81 ± 0.28 0.86 ± 0.29 0.63 ± 0.22 0.67 ± 0.16
FP ± SD 18.84 ± 24.96 41.02 ± 26.07 80.60 ± 21.02 90.49 ± 9.22
Posterior DF ± SD 7.17 ± 0.35 6.71 ± 0.60 6.57 ± 0.66 6.31 ± 0.29
DFV ± SD 0.78 ± 0.33 0.86 ± 0.31 0.60 ± 0.21 0.72 ± 0.18
FP ± SD 16.72 ± 23.49 34.99 ± 24.45 83.35 ± 23.68 94.99 ± 6.25
Lateral DF ± SD 7.18 ± 0.31 6.80 ± 0.54 6.65 ± 0.53 6.51 ± 0.36
DFV ± SD 0.80 ± 0.30 0.83 ± 0.33 0.64 ± 0.26 0.72 ± 0.18
FP ± SD 17.53 ± 22.06 39.24 ± 26.68 83.35 ± 18.76 89.36 ± 15.10
Slow-theta Frontal DF ± SD 4.88 ± 0.15 4.93 ± 0.17 5.01 ± 0.15 5.02 ± 0.14
DFV ± SD 0.55 ± 0.06 0.52 ± 0.07 0.49 ± 0.08 0.50 ± 0.08
FP ± SD 2.23 ± 4.28 10.52 ± 13.29 16.27 ± 21.06 18.77 ± 11.56
Central DF ± SD 4.95 ± 0.17 4.98 ± 0.18 5.16 ± 0.14 5.14 ± 0.13
DFV ± SD 0.52 ± 0.06 0.49 ± 0.06 0.42 ± 0.10 0.43 ± 0.10
FP ± SD 1.21 ± 3.05 9.46 ± 12.37 9.51 ± 14 11.14 ± 12.28
Posterior DF ± SD 4.91 ± 0.14 4.94 ± 0.18 5.11 ± 0.13 5.11 ± 0.15
DFV ± SD 0.54 ± 0.06 0.51 ± 0.06 0.45 ± 0.07 0.45 ± 0.10
FP ± SD 1.11 ± 3.34 6.97 ± 9.25 13.77 ± 23.03 16.15 ± 11.75
Lateral DF ± SD 4.86 ± 0.18 4.94 ± 0.16 5.09 ± 0.15 5.09 ± 0.16
DFV ± SD 0.56 ± 0.05 0.51 ± 0.08 0.44 ± 0.11 0.46 ± 0.09
FP ± SD 0.51 ± 1.15 5.44 ± 6.74 10.76 ± 17.41 11.76 ± 11.99
Fast Theta Frontal DF ± SD 7.20 ± 0.27 6.98 ± 0.32 6.74 ± 0.41 6.55 ± 0.22
DFV ± SD 0.59 ± 0.14 0.62 ± 0.11 0.53 ± 0.12 0.55 ± 0.09
FP ± SD 17.32 ± 21.02 34.4 ± 17.95 66.21 ± 20.86 72.59 ± 10.45
Central DF ± SD 7.31 ± 0.22 7.02 ± 0.31 6.79 ± 0.43 6.69 ± 0.24
DFV ± SD 0.53 ± 0.16 0.60 ± 0.14 0.50 ± 0.11 0.52 ± 0.07
FP ± SD 17.62 ± 24.30 31.56 ± 20.68 71.09 ± 20.34 79.35 ± 11.86
Posterior DF ± SD 7.35 ± 0.21 7.06 ± 0.36 6.76 ± 0.47 6.54 ± 0.20
DFV ± SD 0.52 ± 0.17 0.58 ± 0.16 0.48 ± 0.11 0.52 ± 0.09
FP ± SD 15.60 ± 22.51 28.01 ± 19.35 69.59 ± 27.37 78.85 ± 11.86
Lateral DF ± SD 7.36 ± 0.19 7.09 ± 0.30 6.81 ± 0.41 6.70 ± 0.24
DFV ± SD 0.50 ± 0.15 0.58 ± 0.18 0.49 ± 0.13 0.52 ± 0.08
FP ± SD 17.02 ± 21.95 33.81 ± 24.26 72.59 ± 21.64 77.60 ± 15.63
Alpha Frontal DF ± SD 9.13 ± 0.57 9.40 ± 0.88 8.64 ± 0.21 9.01 ± 0.44
DFV ± SD 0.88 ± 0.40 1.07 ± 0.43 0.85 ± 0.32 1.19 ± 0.27
FP ± SD 80.45 ± 22.14 55.08 ± 24.54 17.52 ± 21 8.64 ± 8.29
Central DF ± SD 9.13 ± 0.65 9.42 ± 0.90 8.48 ± 0.17 8.70 ± 0.39
DFV ± SD 0.82 ± 0.41 1.04 ± 0.40 0.60 ± 0.17 0.87 ± 0.37
FP ± SD 81.16 ± 24.96 58.98 ± 26.07 19.40 ± 21.02 9.51 ± 9.22
Posterior DF ± SD 9.03 ± 0.63 1.06 ± 0.96 8.49 ± 0.18 8.72 ± 0.33
DFV ± SD 0.64 ± 0.35 0.86 ± 0.45 0.62 ± 0.25 0.93 ± 0.37
FP ± SD 83.28 ± 23.49 65.01 ± 24.45 16.65 ± 23.68 5.01 ± 6.25
Lateral DF ± SD 9.12 ± 0.71 0.92 ± 0.82 8.48 ± 0.18 8.61 ± 0.41
DFV ± SD 0.82 ± 0.37 0.82 ± 0.40 0.65 ± 0.24 0.84 ± 0.35
FP ± SD 82.47 ± 22.06 60.76 ± 26.68 16.65 ± 18.76 10.64 ± 15.10
Theta-alpha Frontal DF ± SD 8.79 ± 0.75 8.24 ± 1.29 6.75 ± 0.80 6.45 ± 0.63
DFV ± SD 1.07 ± 0.46 1.29 ± 0.59 0.91 ± 0.27 0.98 ± 0.33
Central DF ± SD 8.81 ± 0.82 8.36 ± 1.30 6.93 ± 0.71 6.68 ± 0.76
DFV ± SD 0.92 ± 0.47 1.30 ± 0.60 0.80 ± 0.25 0.82 ± 0.25
Posterior DF ± SD 8.82 ± 0.79 8.65 ± 1.21 6.78 ± 0.86 6.41 ± 0.58
DFV ± SD 0.78 ± 0.38 1.21 ± 0.75 0.73 ± 0.23 0.84 ± 0.27
Lateral DF ± SD 8.88 ± 0.81 8.42 ± 1.13 6.90 ± 0.71 6.74 ± 0.81
DFV ± SD 0.93 ± 0.41 1.13 ± 0.51 0.79 ± 0.31 0.88 ± 0.35
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QEEG variables that best predicted diagnosis were the theta power
(%) (Wald chi-square = 15.74, df = 1, p < 0.01), the fast-theta FP
(Wald chi-square = 8.1, df = 1, p < 0.01) and the theta-alpha SD
(Wald chi-square = 7.549, df = 1, p < 0.01). ROC analysis (Fig. 7)
yielded AUC = 94% (90.4–97.9%), sensitivity = 92.26% (CI = 80.4–
100%) and specificity = 83.3% (CI = 73.6–93%). Since no significant
differences were found between the PDD and DLB groups for any
of the QEEG variables in the variance analyses, all the QEEG vari-
ables were included in the GEE analysis. This analysis deviated
from the analysis protocol and is therefore included in the supple-mentary material (Supplementary Material 2), without drawing
further conclusions.4. Discussion
Our analysis has revealed several novel findings, including
greater theta-alpha DFV in AD patients compared to controls,
DLB and PDD patients. Moreover, we did not identify any differ-
ences in the DFV between the DLB group compared to controls,
as was previously reported (Bonanni et al., 2016, 2008; Walker
et al., 2000). However, we found a significant, DLB specific positive
Fig. 3. The mean percentage distribution of the total relative power in three frequency bands (Hz): theta (4–7.75), alpha (8–13.5) and beta 20.75), for each of four diagnostic
groups: healthy controls (N = 21), Alzheimer’s disease (AD; N = 18), dementia with Lewy bodies (DLB; N = 17) and Parkinson’s disease dementia (PDD; N = 17) patients, for the
posterior region. Similar observations were made in the frontal, central and lateral regions but are not shown. Error bards indicate the standard deviation.
Fig. 4. The mean dominant frequency (DF) in the theta-alpha (4–13.75 Hz), alpha (8–13.75 Hz) and theta (4–7.75 Hz) frequency ranges, for each of four diagnostic groups:
healthy controls (N = 21), Alzheimer’s disease (AD; N = 18), dementia with Lewy bodies (DLB; N = 17) and Parkinson’s disease dementia (PDD; N = 17) patients, in the frontal,
central, posterior and lateral regions. Error bars indicate the standard deviation (SD), **p < 0.05, **p < 0.01.
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score and slow-theta FP. Our findings confirm the widely reported
shift of EEG power and dominant rhythm – from the alpha towardsthe theta frequency range in the DLB and PDD groups compared to
healthy controls and AD patients (Briel et al., 1999; Barber et al.,
2000; Bonanni et al., 2008). A subtler slowing of the EEG was also
Fig. 5. The mean frequency prevalence (FP; percentage distribution of the mean dominant frequency (DF) in each frequency point in the theta-alpha frequency range with
0.25 Hz resolution) for each of four diagnostic groups: healthy controls (N = 21), Alzheimer’s disease (AD; N = 18), dementia with Lewy bodies (DLB; N = 17) and Parkinson’s
disease dementia (PDD; N = 17) patients, in the (a) frontal, (b) central, (c) posterior and (d) lateral regions.
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nary analysis investigating the possible diagnostic value of QEEG
variables showed that the three QEEG variables describing the
extent of EEG slowing and DFV (theta power, fast-theta FP and
theta-alpha DFV) could predict a DLB versus an AD diagnosis with
high sensitivity and specificity.
A more marked EEG slowing in DLB/PDD groups compared to
healthy controls and AD patients has been extensively reported
in the literature, mostly in posterior derivations (Briel et al.,
1999; Barber et al., 2000; Roks et al., 2008). In our analysis we
looked within four different cortical regions compared to three
regions previously reported (Bonanni et al., 2016, 2008), and anal-
ysed three measures of EEG spectral distribution, the FP, DF and
power, all of which indicated a greater EEG slowing in DLB/PDD
patients compared to AD patients and controls.
In AD patients, EEG slowing of a lesser extent was observed,
that was evident by a shift of FP from the alpha to the fast-theta
and slow-theta ranges compared to healthy controls. This finding
indicates that a higher percentage of measurements of the theta-
alpha DF in time fell in the theta-band rather than in the alpha-
band in AD patients compared to controls. This altered DF distribu-
tion towards lower frequencies in AD was ‘‘masked” with the cal-
culation of the mean theta-alpha DF, as this measure does not
account for variability. The DF in the AD group is highly variable
and can take values towards the higher edge of the alpha band thus
influencing the mean DF. This is evident by the significantly greater
theta-alpha DFV and the trends for greater alpha DFV and alpha DF
in the AD group.
A cholinergic deficit may partly account for the EEG slowing in
LBDs and AD, as the administration of AChEIs can reverse the EEG
slowing in both diseases (Adler et al., 2004; Babiloni et al., 2013;
Bosboom et al., 2009). However, the loss of cholinergic neuronsprojecting to the cortex is greater and has a faster progression in
DLB and PDD compared to AD (Lippa et al., 1999) where the cholin-
ergic deficit is not yet severe at mild stages of the disease (Bohnen
and Albin, 2011). Pathological protein-related synaptic dysfunction
that occurs before neuronal degeneration has also been associated
with cognitive decline in AD and is thought to be even greater in
DLB (Schulz-Schaeffer, 2010; Selkoe, 2002). Thus, a more advanced
cholinergic deficit and synaptic dysfunction in the LBD groups
could account for the greater extent of EEG slowing observed com-
pared to the AD group, particularly given the relatively early dis-
ease stage/cognitive impairment that our participants exhibited.
Our analysis also revealed novel findings regarding temporal
variability in the dominant rhythm as measured by DFV. Previous
studies have shown a significant DFV increase in DLB patients com-
pared to healthy controls, that correlated with CFs measured by
CAF (Bonanni et al., 2008; Walker et al., 2000). Although we did
not find an increase in the DFV of DLB patients compared to con-
trols, we did find a positive correlation between theta DFV and
the CAF score within the DLB group (Bonanni et al., 2015). This cor-
relation was only significant in the theta frequency range, likely
due to the shift of the DF towards these frequencies. A positive cor-
relation was also found between slow-theta FP and the CAF score
in DLB patients. Both these correlations were only seen in the
DLB group and not in the PDD or AD groups.
Given the neuropathological similarities between PDD and DLB
and the absence of other QEEG differences between these groups,
the lack of a correlation between CAF and our QEEG measures in
PDD was unexpected. Previous studies have reported that PDD
patients with high CF scores show an EEG-slowing (Bonanni
et al., 2008) and have more DLB-like symptoms such as visual hal-
lucinations, while patients with lower CF scores resemble PD
(Varanese et al., 2010). This PDD heterogeneity may have affected
Fig. 6. The mean dominant frequency variability (DFV) in the (a) alpha (8–13.5 Hz) and (b) theta-alpha (4–13.75 Hz) frequency ranges, for each of four diagnostic groups:
healthy controls (N = 21), Alzheimer’s disease (AD; N = 18), dementia with Lewy bodies (DLB; N = 17) and Parkinson’s disease dementia (PDD; N = 17) patients, in the frontal,
central, posterior and lateral regions. Error bards indicate the standard deviation (SD), **p < 0.05, **p < 0.01.
Fig. 7. Receiver operating curves (ROC) for a model composed of fast-theta
frequency prevalence (FP), theta power and theta-alpha dominant frequency
variability (DFV), for differentiating between Alzheimer’s disease (AD; N = 18) and
dementia with Lewy bodies (DLB; N = 17) with mild dementia.
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and CAF score in this group. Moreover, DLB patients with parkin-
sonism have more impaired reaction times and vigilance measures
that relate to CFs, compared to patients without motor symptoms,
implying a connection between CFs and dopaminergic impairment
(Ballard et al., 2002). Since PDD is characterised by greater
dopaminergic impairment than DLB, this additional pathology
could have a more dominant aetiological role in the CFs seen in
PDD as compared to DLB and thus be less contingent on factors
(e.g. cholinergic tone) which might drive a QEEG change that asso-
ciates with CFs. Furthermore, fluctuations are likely to have at least
two dimensions (arousal and attention; Bliwise et al., 2012) which
are not discriminated by the CAF scale but which may be differen-
tially expressed in our DLB and PDD groups given arousal/sleepi-
ness is strongly influenced by dopaminergic medications.
Another factor may be the amyloid burden as this is significantly
greater in DLB compared to PDD (Donaghy et al., 2015) and the cor-
tical amyloid-b deposition relates more to dementia severity,
visual hallucinations and delusion in DLB than PDD (McKeith
et al., 2004). DLB is also characterised by a greater amyloid load
in the putamen (Hepp et al., 2016), which is involved in attentional
networks and in DLB has altered functional connectivity that corre-
lates with CAF (Peraza et al., 2014). Improved quantification scales
of fluctuations may help unpick these challenges.
Previous studies have also shown that DLB patients had a signif-
icantly higher DFV compared to AD patients, which did not differ
significantly from controls, and that a higher DFV was an accurate
indicator of DLB versus AD diagnosis (Bonanni et al., 2008). A QEEG
analysis on the same patient cohorts as in this study, but with less
spatial detail, also suggested a greater theta-alpha DFV in AD
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et al., 2018). Here, we found that AD patients had a significantly
higher theta-alpha DFV compared to the other groups in most
regions while DLB patients were not significantly different than
PPD patients or controls. In the current study looking within smal-
ler frequency bands in the theta-alpha range we also identified a
greater alpha DFV in AD patients compared to controls and DLB
patients posteriorly, and to DLB patients alone centrally. These
findings could be part of the pathology or alternatively, the result
of a compensation mechanism that may occur at early stages of
AD. At rest, early stage AD patients may have increased activity
and functional connectivity in resting state networks which corre-
late with a lower MMSE score (Peraza et al., 2016). However, at
more advanced stages activity and connectivity decrease to levels
lower than those seen in controls (Agosta et al., 2012). Therefore,
increases in DFV may be associated with a compensation mecha-
nism in early stage AD.
A number of other factors may account for the discrepancies
between our findings and those of previous studies. The lack of a
greater DFV in DLB patients compared to controls may be attribu-
ted to the fact that the majority of our DLB patients were on
AChEIs, although we would argue that this adds to the clinical rel-
evance of our findings, particularly from a diagnostic perspective;
it is likely that any use of the EEG will be when patients are begin-
ning or have already been initiated on treatment. In DLB patients,
CFs have been shown to correlate with cholinergic imbalances in
networks involved in the resting state (Delli Pizzi et al., 2015).
AChEIs restore this imbalance and improve both the cognitive
symptoms of DLB and the electrophysiological markers, including
the EEG spectrum and connectivity (Onofrj et al., 2003). That said,
it is important to acknowledge that more AD (94.4%) than DLB
(88.2%) patients were on AChEIs in our study groups and the for-
mer group showed greater DFV. However, as outlined above,
cholinergic deficits are greater and occur earlier in DLB compared
to AD (Tiraboschi et al., 2002), while the brainstem cholinergic
innervations of the thalamus are relatively spared in AD
(Mesulam, 2004) but not in DLB (Taylor et al., 2017). Hence, at
the stage of mild dementia AChEIs could have a differential effect
in DLB and AD. Although AChEIs may have normalized the DFV
in DLB patients in relation to healthy individuals, the CAF/DFV cor-
relation was still maintained within the DLB group. In previous
studies, none (Walker et al., 2000), or only a small proportion
(Bonanni et al., 2008) of the patients were on AChEIs. Differences
in the participant cohorts, as well as methodological differences
in the analysis of the recordings must also be considered. Specifi-
cally, we used a different pre-processing and spatial analysis
approach, as well as a different way to estimate DFV; here DFV
was defined as the standard deviation from the mean DF across
epochs, in an epoch-by-epoch basis, while in Bonanni et al.
(2008, 2016), DFV was defined using a visual rating of DF range
on sequential EEG segments.
Finally, we proceeded with a preliminary analysis to investigate
the capacity of the QEEG variables to correctly differentiate
between AD and DLB patients with mild dementia. The theta
power, fast-theta FP and theta-alpha DFV yielded accuracy of 94%
(CI = 90.4–97.9%), sensitivity of 92.26% (CI = 80.4–100%) and speci-
ficity of 83.3% (73.6–93%). The high predictive accuracy of this
model is in-line with previous classifications using QEEG variables,
although different EEG pre-processing and analysis methods were
used (Andersson et al., 2008; Garn et al., 2017).
A few issues relating to this study need to be considered and an
important next step would be the confirmation of our findings in
independent prospective cohorts, especially regarding the ROC
analysis. We excluded the delta frequencies and hence, we might
have missed changes in the QEEG variables within that range. In
addition, the recordings were not always continuous as we focusedon discarding as much of the noise as possible and preferred to
occasionally reject epochs, across all channels. Moreover, the
patients did not undergo post-mortem immunohistological exam-
ination and thus we did not account for mixed AD-DLB pathology
that has been shown to relate to greater cognitive impairment in
DLB patients (Gomperts et al., 2012) and which may alter the QEEG
pattern. However, our clinical diagnostic approaches were robust
enough to enhance the specificity of our group selections. Evidence
for this include DaT scans that were available for 9 of the DLB
patients and were all positive, and a multi-modal MRI/EEG analysis
on data from all the patients that were recruited in the same cohort
as the patients included in this study, where AD and DLB patients
were classified with 90% accuracy (Colloby et al., 2016).
5. Conclusions
Our findings confirm the well-established slowing of the EEG in
the Lewy body dementia groups compared to healthy controls and
AD patients. Although we did not find higher DFV in DLB patients
compared to controls as expected, theta DFV and slow-theta FP
were positively correlated with CFs as measured by CAF. This
DLB specific correlation suggests that a slower and more tempo-
rally variable DF specifically relates to the CFs seen in DLB, and
could reveal differential mechanisms underlying CFs in dementia
subtypes. Another novel finding was a significantly higher DFV in
AD patients compared to the other groups. Exploratory analysis
showed that QEEG measures could predict a DLB versus an AD
diagnosis with high accuracy, sensitivity and specificity. In conclu-
sion, this study supports the hypothesis that QEEG analysis can be
a valuable tool for identifying CFs in DLB and for differential diag-
nosis between dementia subtypes, once replicated with low den-
sity EEG currently used in standard clinical practice after the
feasibility and cost-effectiveness of these methodologies has been
investigated.
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